Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure
Joint Authors
Abo-amer, Yousry Esam-Eldin
Badawi, Rehab
El-Abgeegy, Mohamed
Elsergany, Heba Fadl
Mohamed, Ahmed Abdelhaleem
Mostafa, Sahar Mohamed
Alegaily, Hatem Samir
Soliman, Shaimaa
Elnawasany, Sally
Abd-Elsalam, Sherief
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-07-24
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Background and Aims.
Direct-acting antivirals (DAAs) have made a revolution in hepatitis C virus (HCV) treatment with promising reduction of HCV infection and disease morbidities.
However, unfortunately, treatment failure still occurs in about 5–15% of patients treated with DAA‐based combination regimens.
The primary aim of the study was to assess the efficacy and safety of a quadruple regimen of (sofosbuvir, daclatasvir, and simeprevir with a weight-based ribavirin) in chronic HCV DAAs-experienced patients.
Methods.
This observational, open-label prospective study was carried out on 103 genotype 4 hepatitis C virus-infected patients who failed to achieve SVR12 after sofosbuvir-daclatasvir with or without ribavirin.
Patients were treated for three months with sofosbuvir (400 mg), daclatasvir (60 mg), and simeprevir (150 mg) with a weight-based ribavirin dosage (1000–1200 mg/d).
Response to treatment was determined by quantitative PCR for HCV at 3 months after the end of treatment (SVR12), and adverse events during the treatment were recorded.
Results.
SVR was achieved in 100 patients (97.1%) at week 12 after treatment.
No dangerous or life-threatening adverse events were recorded.
Conclusions.
Retreatment of HCV genotype 4 patients with quadruple therapy is a good therapeutic option and achieves high response rates with minimal side effects.
American Psychological Association (APA)
Abo-amer, Yousry Esam-Eldin& Badawi, Rehab& El-Abgeegy, Mohamed& Elsergany, Heba Fadl& Mohamed, Ahmed Abdelhaleem& Mostafa, Sahar Mohamed…[et al.]. 2020. Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure. Advances in Virology،Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1130691
Modern Language Association (MLA)
Abo-amer, Yousry Esam-Eldin…[et al.]. Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure. Advances in Virology No. 2020 (2020), pp.1-6.
https://search.emarefa.net/detail/BIM-1130691
American Medical Association (AMA)
Abo-amer, Yousry Esam-Eldin& Badawi, Rehab& El-Abgeegy, Mohamed& Elsergany, Heba Fadl& Mohamed, Ahmed Abdelhaleem& Mostafa, Sahar Mohamed…[et al.]. Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure. Advances in Virology. 2020. Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1130691
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1130691